조직공학 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 지역별, 부문별 예측(2025-2030년)

Tissue Engineering Market Growth & Trends:

The global tissue engineering market size is estimated to reach USD 43.13 billion by 2030, growing at an estimated CAGR of 14.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of chronic diseases, such as cardiovascular diseases, diabetes, and orthopedic disorders, has driven the demand for tissue engineering solutions that can repair or replace damaged tissues. Advances in biomaterials, 3D bioprinting, stem cell research, and gene editing techniques have propelled the field of tissue engineering, enabling the development of complex and functional tissues.

The allogeneic tissue transplant method effectively addresses the challenges and limitations associated with the use and accessibility of autologous transplants. In addition, the advancement of specialized procedures, such as implant fixing and sterilization, aimed at converting allogeneic implants into biostatic implants, is anticipated to boost revenue generation in this market.

Tissue regeneration technology is gaining popularity due to its effective products and low rejection rates, leading to an increase in regeneration treatments. Pre-clinical research is currently focused on the use of tissue-engineered vascular grafts in cardiovascular surgery and treatment. Moreover, tissue-engineered bladders can now be successfully implanted outside of the patient's body. Despite these advancements, the market's growth is hindered by challenges such as the high cost of product development and ethical concerns surrounding stem cell research and tissue-engineered products.

Tissue Engineering Market Report Highlights:

• The orthopedics, musculoskeletal, & spine segment held the largest revenue of 59.21% market share in 2024, owing to the increasing prevalence of musculoskeletal disorders.
• North America dominated the market and accounted for the largest revenue share of 51.30% in 2024, owing to rising awareness of stem cell therapy, the growing geriatric population, and the rising incidence of chronic diseases.
• The market for tissue engineering in Asia Pacific is estimated to witness the fastest CAGR of 19.04% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Application
  • 1.1.2. Regional scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Tissue Engineering Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in stem cell technology & tissue engineering
    • 3.2.1.2. Rise in number of clinical studies for Tissue Engineering and tissue engineering
    • 3.2.1.3. Increasing tissue engineering research funding
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of product development
    • 3.2.2.2. Ethical concerns related to stem cell research & tissue engineered product
    • 3.2.2.3. Clinical issues pertaining to development & implementation of stem cell therapies
• 3.3. Tissue Engineering Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Application Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Tissue Engineering Market Application Movement Analysis
• 4.3. Global Tissue Engineering Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
• 4.4. Cord blood & Cell banking
  • 4.4.1. Cord blood & Cell banking market estimates and forecast 2018 - 2030 (USD Million)
• 4.5. Cancer
  • 4.5.1. Cancer market estimates and forecast 2018 - 2030 (USD Million)
• 4.6. GI/Gynecology
  • 4.6.1. GI/Gynecology therapy market estimates and forecast 2018 - 2030 (USD Million)
• 4.7. Dental
  • 4.7.1. Dental market estimates and forecast 2018 - 2030 (USD Million)
• 4.8. Skin & Integumentary
  • 4.8.1. Skin & Integumentary market estimates and forecast 2018 - 2030 (USD Million)
• 4.9. Urology
  • 4.9.1. Urology market estimates and forecast 2018 - 2030 (USD Million)
• 4.10. Orthopedics, Musculoskeletal, & Spine
  • 4.10.1. Orthopedics, Musculoskeletal, & Spine market estimates and forecast 2018 - 2030 (USD Million)
• 4.11. Neurology
  • 4.11.1. Neurology market estimates and forecast 2018 - 2030 (USD Million)
• 4.12. Cardiology & Vascular
  • 4.12.1. Cardiology & Vascular market estimates and forecast 2018 - 2030 (USD Million)
• 4.13. Others
  • 4.13.1. Others market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

• 5.1. Regional Dashboard
• 5.2. Tissue Engineering Market: Share By Region, 2024 & 2030
• 5.3. North America
  • 5.3.1. North America Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Key Country Dynamics
    • 5.3.2.2. Competitive Scenario
    • 5.3.2.3. Regulatory Framework
    • 5.3.2.4. U.S. Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key Country Dynamics
    • 5.3.3.2. Competitive Scenario
    • 5.3.3.3. Regulatory Framework
    • 5.3.3.4. Canada Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key Country Dynamics
    • 5.3.4.2. Competitive Scenario
    • 5.3.4.3. Regulatory Framework
    • 5.3.4.4. Mexico Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. Europe Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.4.2. UK
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Competitive Scenario
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. UK Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.4.3. Germany
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Competitive Scenario
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Germany Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.4. France
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Competitive Scenario
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. France Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.5. Italy
    • 5.4.5.1. Key Country Dynamics
    • 5.4.5.2. Competitive Scenario
    • 5.4.5.3. Regulatory Framework
    • 5.4.5.4. Italy Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.6. Spain
    • 5.4.6.1. Key Country Dynamics
    • 5.4.6.2. Competitive Scenario
    • 5.4.6.3. Regulatory Framework
    • 5.4.6.4. Spain Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key Country Dynamics
    • 5.4.7.2. Competitive Scenario
    • 5.4.7.3. Regulatory Framework
    • 5.4.7.4. Sweden Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Key Country Dynamics
    • 5.4.8.2. Competitive Scenario
    • 5.4.8.3. Regulatory Framework
    • 5.4.8.4. Norway Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.4.9. Denmark
    • 5.4.9.1. Key Country Dynamics
    • 5.4.9.2. Competitive Scenario
    • 5.4.9.3. Regulatory Framework
    • 5.4.9.4. Denmark Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Asia Pacific Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. China Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.5.3. Japan
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Japan Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.4. India
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Competitive Scenario
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. India Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.5. Australia
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Competitive Scenario
    • 5.5.5.3. Regulatory Framework
    • 5.5.5.4. Australia Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Competitive Scenario
    • 5.5.6.3. Regulatory Framework
    • 5.5.6.4. Thailand Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.5.7. South Korea
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Competitive Scenario
    • 5.5.7.3. Regulatory Framework
    • 5.5.7.4. South Korea Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Latin America Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.6.2. Brazil
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Brazil Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Argentina Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. MEA Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.7.2. South Africa
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Competitive Scenario
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. South Africa Tissue Engineering Market, 2018 - 2030 (USD Million)
  • 5.7.3. Saudi Arabia
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Competitive Scenario
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. Saudi Arabia Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.7.4. UAE
    • 5.7.4.1. Key Country Dynamics
    • 5.7.4.2. Competitive Scenario
    • 5.7.4.3. Regulatory Framework
    • 5.7.4.4. UAE Tissue Engineering Testing Market, 2018 - 2030 (USD Million)
  • 5.7.5. Kuwait
    • 5.7.5.1. Key Country Dynamics
    • 5.7.5.2. Competitive Scenario
    • 5.7.5.3. Regulatory Framework
    • 5.7.5.4. Kuwait Tissue Engineering Testing Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Strategy Mapping
• 6.3. Company Position Analysis, 2024
• 6.4. Company Profiles/Listing
  • 6.4.1. Zimmer Biomet Holdings, Inc.
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. AbbVie (Allergan)
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. Becton, Dickinson and Company
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. B. Braun
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. Integra LifeSciences Corporation
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. Organogenesis Holdings Inc.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. Medtronic
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives
  • 6.4.8. ACell, Inc.
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic Initiatives
  • 6.4.9. Athersys, Inc.
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic Initiatives
  • 6.4.10. Tissue Regenix Group plc
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic Initiatives
  • 6.4.11. Stryker Corporation
    • 6.4.11.1. Overview
    • 6.4.11.2. Financial Performance
    • 6.4.11.3. Product Benchmarking
    • 6.4.11.4. Strategic Initiatives
  • 6.4.12. RTI Surgical, Inc.
    • 6.4.12.1. Overview
    • 6.4.12.2. Financial Performance
    • 6.4.12.3. Product Benchmarking
    • 6.4.12.4. Strategic Initiatives
  • 6.4.13. ReproCell, Inc.
    • 6.4.13.1. Overview
    • 6.4.13.2. Financial Performance
    • 6.4.13.3. Product Benchmarking
    • 6.4.13.4. Strategic Initiatives
  • 6.4.14. Baxter International, Inc.
    • 6.4.14.1. Overview
    • 6.4.14.2. Financial Performance
    • 6.4.14.3. Product Benchmarking
    • 6.4.14.4. Strategic Initiatives